This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Apollo Endosurgery Toekomstige groei
Future criteriumcontroles 2/6
Belangrijke informatie
6.5%
Groei van de winst
7.2%
Groei van de winst per aandeel
Medical Equipment winstgroei | 15.8% |
Inkomstengroei | 32.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 04 Apr 2023 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2025 | 181 | N/A | -31 | N/A | 1 |
12/31/2024 | 111 | -36 | -28 | N/A | 2 |
12/31/2023 | 89 | -36 | -30 | N/A | 3 |
12/31/2022 | 77 | -40 | -34 | -31 | N/A |
9/30/2022 | 72 | -41 | -28 | -25 | N/A |
6/30/2022 | 68 | -36 | -25 | -23 | N/A |
3/31/2022 | 66 | -28 | -21 | -19 | N/A |
12/31/2021 | 63 | -25 | -16 | -14 | N/A |
9/30/2021 | 60 | -18 | -14 | -13 | N/A |
6/30/2021 | 56 | -14 | -15 | -14 | N/A |
3/31/2021 | 45 | -17 | -19 | -19 | N/A |
12/31/2020 | 42 | -23 | -21 | -21 | N/A |
9/30/2020 | 41 | -26 | -26 | -25 | N/A |
6/30/2020 | 40 | -32 | -27 | -26 | N/A |
3/31/2020 | 48 | -35 | -27 | -26 | N/A |
12/31/2019 | 51 | -27 | -27 | -26 | N/A |
9/30/2019 | 54 | -39 | -24 | -23 | N/A |
6/30/2019 | 57 | -40 | -21 | -20 | N/A |
3/31/2019 | 58 | -40 | -24 | -22 | N/A |
12/31/2018 | 61 | -46 | -26 | -23 | N/A |
9/30/2018 | 62 | -35 | -26 | -23 | N/A |
6/30/2018 | 64 | -30 | -27 | -24 | N/A |
3/31/2018 | 66 | -27 | -20 | -17 | N/A |
12/31/2017 | 64 | -27 | -15 | -13 | N/A |
9/30/2017 | 64 | -33 | -18 | -16 | N/A |
6/30/2017 | 63 | -36 | -16 | -14 | N/A |
3/31/2017 | 63 | -41 | -14 | -12 | N/A |
12/31/2016 | 65 | -41 | -15 | -13 | N/A |
9/30/2016 | 66 | -36 | N/A | -8 | N/A |
6/30/2016 | 66 | -38 | N/A | -7 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: HQ8F is forecast to remain unprofitable over the next 3 years.
Winst versus markt: HQ8F is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: HQ8F is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: HQ8F's revenue (32% per year) is forecast to grow faster than the German market (3.3% per year).
Hoge groei-inkomsten: HQ8F's revenue (32% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if HQ8F's Return on Equity is forecast to be high in 3 years time